Introducing the
Oncomap™ ExTra test

The Oncomap ExTra test provides treating physicians with vital interpreted information they need to understand changes to their patient’s genomic profile, and outline an optimal therapeutic treatment plan. Conditions that may benefit from this approach include treatment of advanced, refractory, rare, or aggressive cancers.

Why choose the Oncomap ExTra test?

The Oncomap ExTra test combines the ultra-comprehensive genomic insights you expect from whole exome, whole transcriptome sequencing with the actionability and accessibility you and your patients need to inform crucial treatment decisions.

  • Compare genes in both tumor (somatic) and normal (germline) DNA.
  • Concomitant analysis of germline DNA allows for quick identification of true somatic alterations and maximizes the likelihood of identifying
    tumor-specific variations with an accuracy of >99%.

Pioneering Our Tumor-Sequencing Approach Since 2010

The data from this research suggests that matched tumor-normal sequencing analyses are essential for precise identification and interpretation of somatic and germline alterations, having important implications for the diagnostic and therapeutic management of cancer patients.

Read the full research articles

Apply Deeper Genomic Insights

Whole Exome Sequencing

Identifies point mutations, amplifications and deletions, and translocations/structural variants in the full set of protein-coding genes and in therapeutically actionable non-coding regions (e.g., TERT promoter, common translocation junctions).

Whole Transcriptome Sequencing

Identifies the expression of RNA transcripts that may guide therapy (e.g., targetable gene fusions).

  • Tumor/normal exome subtraction—to help clearly distinguish somatic mutation from benign background variation

  • Results are presented in a single, integrated report with a cover page summarizing potentially clinically actionable findings, including:

    • Available therapeutic options

    • Clinical trial options

    • Markers to help guide checkpoint inhibitor therapy (MSI, TMB, and optional PD-L1 IHC)

  • Turnaround time is 14 days

  • Unstained slides: 10 from a single tumor, ≥ 50 microns total + H&E slide

Reports Are Easy to Read and Use

Final report provides physicians with a list of actionable variants, potential treatment therapies, and available clinical trials. Complete biomarker summaries describe related tumor-specific drug evidence.